Evaluation of drug promotional literature directed to consumers and physicians
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20160765Keywords:
Evaluation, Drug promotional brochures, DTC, Direct-to-physician, AdvertisementAbstract
Background: The present study aims at analysing promotional brochures and direct-to-consumer advertisements using the criteria for ethical medicinal drug promotion compiled by World Health Organization.
Methods: Using World Health Organization criteria for ethical medicinal drug promotion, thirty brochures were evaluated for their fulfilment of the criteria and claims they are making. Also eight Direct to Consumer (DTC) TV advertisements were coded for their claimed indications and the factors used to attract consumers. An overview of what impact does drug promotion has provided through reviewing the published literature.
Results: Brochures and advertisements directed to physicians were found to lack information with regard to generic (17.2%), brand (0%), indication (13.8%), dosage regimen (27.5%), safety information (62%), references (10.3%), manufacture (3.4%), safety (24.1%), efficacy (34.5%), suitability (20.6%), pharmacokinetics (3.4%) pharmaceutical property (3.4%) and extravagant emotional claims (3.4%). Information lacking in DTC TV advertisements include, risk factors (62.5%), alternative treatment (62.5%), indications (37.5%), side effects (75%), contraindications\precautions (50%), and sources for more information about the promoted drug (25%).
Conclusions: Drug advertisements presented to physicians or directed to consumers did not fully satisfy the WHO criteria and their lack of essential information may lead to medication misuse.
References
Bansal RK, Das S. Unethical relationship between doctors and drugs companies. J Ind Acad Foren Med. 2005;27(1):40-42.
Rongey CM. Advertising and the pharmaceutical industry. Encyclopedia of Drugs, Alcohol, and Addictive Behavior. 2011. Encyclopedia.com: http://www.encyclopedia.com/doc/1G2-3403100029.html. Accessed 31 October 2015)
Cardarelli R, Licciardone JC, Taylor L. A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: Is what they tell us important and true. BMC Family Practice. 2005;7(13).
Mali SN, Sujata D, Bachewar NP. Evaluation of rationality of promotional drug literature using world health organization guidelines. Ind J Pharmacol. 2010;42(5):267-272.
Sharif SI, Abduelkarem AR. Analysis of written pharmaceutical advertisements in Dubai & Sharjah. Saudi Pharmaceu J. 2008;16:252-7.
Buckley J. Pharmaceutical marketing - time for change. Electronic Journal of Business Ethics and Organization Studies. 2004;9(2):4-11.
Higgins SP. Drug representatives: Giving you lunch or stealing your soul. Dermatology Online Journal. 2007;13(4):5.
Shaw A. Direct-to-consumer advertising of pharmaceuticals. http://www.csa.com/discovery guides/ direct/review.php. 2008. Accessed 12 November 2011.
Kaiser Family Foundation. Impact of direct-to-consumer advertising on prescription drug spending No. 6084). Washington, DC: Kaiser Family Foundation. http://www.kff.org/rxdrugs/ loader.cfm?url=/commonspot/security/getfile.cfm&PageID=14378/ Accessed 17 November 2011.
Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG. Demand effects of recent changes in prescription drug promotion. In D. M. Cutler, & A. M. Garber (Eds.), Frontiers in health policy research (6th ed., pp. 1-26) MIT Press. 2003.
Pauline N, Herxheimer A, Lexchin J, Mansfield P. What we know, what we have yet to learn - reviews of materials No. EDM Research Series No. 032). World Health Organization and Health Action International. 2004. http://www.drugpromo.info/, Accessed 05 December 2011.
Villanueva P, Peiró S, Librero J, Pereiró I. Accuracy of pharmaceutical advertisements in medical journals. The Lancet. 2003;361(9351):27-32.
WHO. Ethical criteria for medicinal drug promotion. (Essential Drugs Monitor No. 017). Geneva: World Health Organization. 1988. Accessed 04 December 2015
Manchanda P, Honka E. The effects and role of direct-to-physician marketing in the pharmaceutical industry: An integrative review. Yale J Health Policy Law Ethics. 2005;5(2):785-822.
Cohen, EP. Direct-to the-public advertisement of
prescription drugs. N Eng J Med. 1988;318(6):373-6.
Kessler DA, Pines WL. The federal regulation of prescription drug advertising and promotion. JAMA. 1990;264(18):2409-15.
Bloom BS, Iannacone RC. Internet availability of prescription pharmaceuticals to the public. Ann Int Med. 1999;131(11):830-3.
Smith R. Medical journals and pharmaceutical companies: Uneasy bedfellows. Br Med J. 2003;326(7400):1202-5.
Robinson AR, Hohmann KB, Rifkin JI, Topp D, Gilroy CM, Pickard JA, et al. Direct-to-consumer pharmaceutical advertising. physician and public opinion and potential effects on the physician-patient relationship . Arch Intern Med. 2004;164(4):427-32.
Bloom BS, Iannacone RC. Internet availability of prescription pharmaceuticals to the public. Ann Int Med. 1999;131(11):830-3.
Hughes CM, McElnay JC. Fleming GF: Benefits and risks of self medication. Drug Saf. 2001;24:1027-37.
Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007;357(7):673-81.
Flynn LT. Does direct to consumer advertising of prescription drugs benefit the public’s health? – yes American Council on Science and Health.1999;11(4).
Calfee J. Public policy issues in direct-to-consumer advertising of prescription drugs. Journal Public Policy and Marketing. 2002;21(2):174-9.
